Head to Head Review: Shattuck Labs (NASDAQ:STTK) and Kyntra Bio (NASDAQ:KYNB)

Shattuck Labs (NASDAQ:STTK) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Risk & Volatility

Shattuck Labs has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Insider and Institutional Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Shattuck Labs and Kyntra Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	9	3	3.08
Kyntra Bio	2	0	5	0	2.43

Shattuck Labs currently has a consensus target price of $13.70, suggesting a potential upside of 182.47%. Kyntra Bio has a consensus target price of $36.80, suggesting a potential upside of 930.81%. Given Kyntra Bio’s higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Shattuck Labs.

Profitability

This table compares Shattuck Labs and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-46.46%	-43.56%
Kyntra Bio	2,199.13%	N/A	-47.27%

Earnings & Valuation

This table compares Shattuck Labs and Kyntra Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.00 million	493.92	-$48.81 million	($0.51)	-9.51
Kyntra Bio	$6.44 million	2.25	$183.45 million	$45.30	0.08

Kyntra Bio has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company’s research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.